Ixo-vec reduced anti-VEGF injection frequency and was well tolerated in patients with wet AMD. A phase 3 pivotal trial ...

Small doses of the involuntary nervous system blocker, atropine, may offer a non-invasive treatment for symptomatic vitreous ...

IRX-101, a new antiseptic tested in patients receiving eye injections for macular degeneration, resulted in less pain and ...

Most of the attention has been on Medicaid cuts, but the reconciliation bill and CMS rule changes will also slash enrollment ...

In a study in mice, a wireless implant was able to release glucagon as an emergency treatment for hypoglycemia, a serious ...

The FDA has approved VIZZ, a once-daily, preservative-free eye drop that improves near vision in adults with presbyopia for up to 10 hours.

Results show dosing intervals increasing by two weeks or longer for patients with diabetic macular edema and neovascular (wet) age-related macular degeneration who switch to Eylea HD.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

More than 60 companies pledged to improve healthcare technology during a White House “Make Health Tech Great Again” event ...

New findings reveal that early treatment with Syfovre significantly improves vision preservation in geographic atrophy ...

Anti-VEGF and anti-complement therapies work on distinct mechanisms in age-related macular degeneration, and both may be required to treat patients with advanced disease or complex cases.

PER-001, delivered through a slow-release, dissolvable implant in the vitreous cavity of the eye, is designed to block ...